Boston Scientific agrees to pay an undisclosed amount to settle patent infringement cases against OrbusNeich in the U.S. and Europe over coronary stent technology.
Boston Scientific (NYSE:BSX) agreed to pay an undisclosed amount to put its long-running patent war with OrbusNeich Medical to rest.
Boston Scientific's latest legal updates provides some insight into a possible end in the long-running Guidant battles, a locking of arms in the Guidezilla disputes and minor progress in a few other litigations.
Medical device giant Boston Scientific (NYSE:BSX) listed no fewer than a dozen legal battles in its latest financial report, notching some wins, some losses and some seemingly circuitous fights without end.
Medical device titan Boston Scientific provides updates on some of its long-standing legal battles, including a mass-complaint from the Iraqi government, a dwindling whistleblower lawsuit over stent marketing and the never-ending patent spat with OrbusNeich.
Boston Scientific (NYSE:BSX) is no stranger to the court room, and its latest quarterly release is a testament to the company's legal tenacity.
OrbusNeich says its Combo dual-therapy stent is the 1st drug-eluting stent to win CE Mark approval in the European Union that combines traditional DES technology with the stimulation of healthy blood vessel growth.
OrbusNeich Medical said it got the green light in Europe for its Combo dual-therapy stent, calling it the 1st such device to both promote healthy tissue growth and prevent the stent from being engulfed by tissue growth.
Boston Scientific denies allegations by stents rival OrbusNeich that it tried to block the seizure of stants whose importation is banned in Germany.
A German court issues a 2nd injunction barring Boston Scientific from importing drug-eluting stents into that country.
OrbusNeich exercises its legal win by blocking the import of Boston Scientific's Promus, Taxus, Omega and Synergy stents into Germany.
OrbusNeich Medical wasted no time in enforcing a patent win against Boston Scientific (NYSE:BSX), announcing that it is blocking German imports of its rival's cardiac stents.